Skip to content
Search

Latest Stories

Over 58m patients seek informal consultations from community pharmacy each year, PSNC audit reveals

Over 1.1 million patients seek informal consultations a week from community pharmacies located across England, according to latest data from PSNC.

Its 2021 Pharmacy Advice Audit revealed that annually 58 million such consultations are being conducted by community pharmacy teams in the country.


The Pharmaceutical Services Negotiating Committee’s latest findings follow the audit of almost 6,000 community pharmacies held earlier this year, alongside a series of resources to promote the value of pharmacy advice.

During the audit, 114,898 informal patient consultations were recorded, with the average pharmacy carrying out around 17 consultations per day.

The audit results indicate that every week pharmacies help over 730,000 people seeking advice for symptoms and over 263,000 people about an existing medical condition.

In almost a quarter of these informal consultations (24 per cent), people sought advice about Covid-19.

Pharmacy teams were able to provide expert advice to an incredible 97 per cent of those who sought it, with just over half (54 per cent) of those consultations also led to the sale of a medicine.

The average staff time per consultation was just over five minutes. However, during this audit, 61 per cent of pharmacies reported being under intense pressure, with an average score of 7.66 out of 10 given for pharmacy pressure.

Almost half of people seeking advice said without pharmacy to turn to they would have attended a GP practice, and 8.6 per cent said they had already been unable to access another part of the healthcare system.

A further 9 per cent and 2.5 per cent of consultations were the product of informal referrals from General Practice and NHS111.

The audit showed that every week unpaid pharmacy advice is preventing 70,000 people from going to A&E or an NHS walk-in centre and saving more than 74 appointments for every single GP practice across England.

PSNC chief executive Simon Dukes said: “Thank you to all the pharmacy teams who took part in this PSNC audit. It will provide an important dataset for use in our negotiations with Government.

"The audit results help showcase the incredible work that community pharmacies do every single day and the value that this brings to their patients. They also explore the Covid impact: the additional pressures this has brought for the workforce and the increasing reliance the public has had on pharmacy services during the pandemic.”

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less